Primera

Primera Therapeutics is a biotechnology company dedicated to developing the first curative therapies for mitochondrial diseases through precise DNA editing. The company's core technology is the mitoTALEN platform, which enables the targeted elimination of mutated mitochondrial DNA while sparing healthy genomes. This approach addresses the underlying cause of heteroplasmic mitochondrial disorders, which currently have no FDA-approved disease-modifying treatments. Primera was launched as a joint venture between Mayo Clinic and Hibiscus BioVentures to translate decades of research into clinical applications. Their pipeline includes programs for Pearson Syndrome, MELAS, and other mitochondrial DNA-related conditions. By leveraging a strategic partnership with Cellectis for TALEN technology, Primera is positioned at the forefront of mitochondrial medicine.